Remimazolam

Remimazolam as an Alternative to Propofol in Oral Surgeries

Retrieved on: 
Monday, January 29, 2024
BSI, BIS, Patient, Heart rate, Bradycardia, Intubation, Incidence, EEG, DDS, Fentanyl, Consciousness, PONV, Propofol, Delirium, Remimazolam, Oral and maxillofacial surgery, Movement, Comparison, PSI, Doctor of Philosophy, Arousal, Remifentanil, Hypotension, Vomiting, Blood pressure, Tsurumi University, Dentistry

LAWRENCE, Kan., Jan. 29, 2024 /PRNewswire-PRWeb/ -- Anesthesia Progress – Propofol has been a widely used intravenous sedative for oral and maxillofacial surgeries because of advantages like less postoperative nausea and vomiting (PONV), no air pollution issues, a fast, clean emergence profile, and less emergence delirium. However, propofol has some significant downsides, including cardiovascular depression, injection pain, high fat content, and not being water-soluble. Recently, remimazolam has been suggested as an alternative to propofol in dental procedures because it does not contain similar fat, does not cause injection pain, and does not have cardiovascular depression potential. But is remimazolam as safe and effective as propofol?

Key Points: 
  • Recently, remimazolam has been suggested as an alternative to propofol in dental procedures because it does not contain similar fat, does not cause injection pain, and does not have cardiovascular depression potential.
  • The results of this study show that remimazolam could be considered a suitable alternative to propofol.
  • They go on to note that "remimazolam appears to be a safe alternative to propofol for providing intubated general anesthesia for oral and maxillofacial surgery procedures."
  • Full text of the article, "Comparison of Remimazolam and Propofol for Intubated General Anesthesia for Oral and Maxillofacial Surgery," Anesthesia Progress, Vol.

EQS-News: PAION AG to issue approximately 4.8 million shares at EUR 1.90 per share in capital increase with subscription rights

Retrieved on: 
Thursday, October 26, 2023
Frankfurt Stock Exchange, European Investment Bank, Patent, ISIN, Financial Oversight and Management Board for Puerto Rico, BofA Securities, Supervisory board, Nice, Partnership, EUR, Federal Gazette, CFO, Investment, Remimazolam, Anesthesia, Security (finance)

For further details on the capital increase with subscription rights, please see the subscription offer provisionally planned to be published in the electronic Federal Gazette on 23 October 2023 and on the website of PAION AG ( www.paion.com ).

Key Points: 
  • For further details on the capital increase with subscription rights, please see the subscription offer provisionally planned to be published in the electronic Federal Gazette on 23 October 2023 and on the website of PAION AG ( www.paion.com ).
  • PAION will receive gross proceeds of about EUR 9 million for the capital increase with subscription rights.
  • Tilmann Bur, CEO of PAION AG, commented: "This capital increase is an important step towards achieving our growth targets.
  • Sebastian Werner, CFO of PAION AG, added: ”This capital increase marks a first important milestone in our overarching financing strategy.

Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference

Retrieved on: 
Wednesday, August 30, 2023
Midazolam, Critical care, Medical Affairs Bureau, Society, Remimazolam, Central nervous system, DSM-IV codes, MD, Patient, Nursing care plan, Health, Fentanyl, Anesthesiology

WOODCLIFF LAKE, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has been selected to present a platform presentation at the Society for Neuroscience in Anesthesiology and Critical Care (“SNACC”) Annual Meeting being held September 8-10, 2023, in Alexandria, VA.

Key Points: 
  • WOODCLIFF LAKE, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has been selected to present a platform presentation at the Society for Neuroscience in Anesthesiology and Critical Care (“SNACC”) Annual Meeting being held September 8-10, 2023, in Alexandria, VA.
  • The conference is designed to meet the educational needs of neurosurgical and critical care anesthesiologists and neuroscientists involved in the care of patients with neurological disorders.
  • “Byfavo is the first new sedative to come to market in over 20 years, and we are extremely grateful for the opportunity to present this analysis to our esteemed colleagues in the perioperative neuroscience community,” stated Mike Greenberg, MD, Vice President of Medical Affairs at Eagle Pharmaceuticals.
  • “Gaining a better understanding of the potential impact of sedation agents on the central nervous system – as they relate to both short- and long-term changes in cognitive function – should help provide more precise patient care.

Eagle Pharmaceuticals Reports Second Quarter 2023 Results

Retrieved on: 
Tuesday, August 8, 2023
Share repurchase, QIDP, Bronchopneumonia, Marketing, Food, Eagle, Type, Acquisition, Patient, Growth, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Pemetrexed, Tariff, Safety, Breast cancer, Film industry, Video game, Pharmaceutical industry, Tutoring, Remimazolam

“We delivered a strong second quarter with impressive earnings and revenue, continuing the positive trajectory from an outstanding 18 months of business performance,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.

Key Points: 
  • “We delivered a strong second quarter with impressive earnings and revenue, continuing the positive trajectory from an outstanding 18 months of business performance,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.
  • Depending upon recruitment rates, Eagle anticipates having its 50% interim report around the first half of 2024.
  • Total revenue for the second quarter of 2023, was $64.6 million, as compared to $74.1 million for the second quarter of 2022.
  • Second quarter 2023 royalty revenue was $21.7 million, compared to $24.9 million in the prior year quarter.

EQS-News: PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR BYFAVO IN GENERAL ANESTHESIA IN THE PHILIPPINES

Retrieved on: 
Monday, July 17, 2023
Maintenance, Remimazolam, Frankfurt Stock Exchange, SEA, Anesthesia, ISIN, Nursing care plan, Pharmaceutical industry

Hana Pharm plans to launch the product in the Philippines in the fourth quarter of this year.

Key Points: 
  • Hana Pharm plans to launch the product in the Philippines in the fourth quarter of this year.
  • The approval of ByfavoTM in general anesthesia in the Philippines is the first approval in the six Southeast Asian (SEA) countries.
  • Taehong Choi, CEO at Hana Pharm, commented: "The approval obtained in the Philippines is a testament to Hana Pharm’s global business capabilities.
  • PAION granted Hana Pharm exclusive rights to develop and commercialize Byfavo® for the South Korean market in 2013.

Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance

Retrieved on: 
Thursday, June 15, 2023
Acacia, Maintenance, Food and Drug Administration Safety and Innovation Act, QIDP, Bronchopneumonia, Marketing, Food, Eagle, Progress, GAIN, Vomiting, Acquisition, Patent, PONV, Patient, Physician, NCE, Nursing, Growth, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Pemetrexed, Tariff, Safety, Breast cancer, Pharmaceutical industry, Remimazolam

“As we approach midyear 2023, our business remains strong, and we are pleased with the positive growth trajectory in our key commercial products. Through our well-trained and experienced sales force -- made up of 50 reps on the hospital side of the business and 25 focused on oncology -- for the quarter to date, Barhemsys® and Byfavo® have already topped the sales number posted in the first quarter of 2023, and PEMFEXY® has achieved an 18% market share in early Q2. We are pleased to see these two assets gaining uptake in the hospital and reflecting the value we saw when we originally decided to make the acquisition,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.

Key Points: 
  • WOODCLIFF LAKE, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and reiterated its 2023 financial guidance.
  • “As we approach midyear 2023, our business remains strong, and we are pleased with the positive growth trajectory in our key commercial products.
  • Eagle anticipates continued growth in net sales of PEMFEXY in the remainder of 2023 as compared to 2022.
  • Guidance: The Company reaffirms previously provided 2023 full-year guidance.

Eagle Pharmaceuticals Granted Unique J-Code for Byfavo®¹ (remimazolam for injection) from CMS

Retrieved on: 
Monday, May 1, 2023
Government, Healthcare Common Procedure Coding System, Medicare Advantage, HCPCS, Remimazolam, Patient, Centers for Medicare & Medicaid Services, Pharmaceutical industry, Medicare

WOODCLIFF LAKE, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Centers for Medicare & Medicaid Services (“CMS”) has established a unique, product-specific billing code for Byfavo®1 (remimazolam for injection), a short-acting sedative for procedures lasting 30 minutes or less. This new Healthcare Common Procedure Coding System (HCPCS) Level II code (“J-code”) is J2249 “Injection, remimazolam, 1 mg.” The J-code will be effective on July 1, 2023.

Key Points: 
  • WOODCLIFF LAKE, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Centers for Medicare & Medicaid Services (“CMS”) has established a unique, product-specific billing code for Byfavo®1 (remimazolam for injection), a short-acting sedative for procedures lasting 30 minutes or less.
  • This new Healthcare Common Procedure Coding System (HCPCS) Level II code (“J-code”) is J2249 “Injection, remimazolam, 1 mg.” The J-code will be effective on July 1, 2023.
  • “The establishment of a unique J-code for Byfavo is an important step in facilitating reimbursement and broadening access to this innovative sedation drug.
  • Byfavo offers a fast onset, titratability, and rapid recovery for quick discharge, potentially leading to shorter procedure times.

EQS-News: PAION AG announces change in Management Board

Retrieved on: 
Wednesday, November 30, 2022
Marketing, Diple, Pleasure, Remimazolam, University, Financial Oversight and Management Board for Puerto Rico, Frankfurt Stock Exchange, AGR, Aktiengesellschaft, RTÉ Executive Board, Patient, Angiotensin, Critical care, Anesthesia, ISIN, Multiplicity of infection, Paion, Health, Abbott, Infection, Hypotension, Supervisory board, Septic, University Hospital Bonn, Distributive shock, EU, Management, Pharmaceutical industry, Pfizer

Dr. James Phillips leaves PAION AG as of 30 November 2022 by mutual agreement with the company.

Key Points: 
  • Dr. James Phillips leaves PAION AG as of 30 November 2022 by mutual agreement with the company.
  • Furthermore, Mr Gregor Siebert, currently a member of the Supervisory Board, will be appointed by the Supervisory Board of PAION AG as a member of the Management Board and Chairman of the Management Board pursuant to section 105 (2) of the German Stock Corporation Act (AktG) for a period from 1 December 2022 until 30 November 2023 to succeed Dr. Phillips.
  • At the same time, we wish Mr. Siebert every success in his role as CEO and Chairman of the Management Board.
  • Gregor Siebert has been a member of the Supervisory Board of PAION AG since May 2022.

EQS-News: PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN

Retrieved on: 
Sunday, November 27, 2022
Marketing, Food, Frankfurt Stock Exchange, Life, Partnership, Physician, Patient, Angiotensin, Critical care, Anesthesia, ISIN, Remimazolam, Maintenance, Medicine, Multiplicity of infection, Health, Hypotension, TTY, Septic, Distributive shock, EU, Dentistry, Pharmaceutical industry

This will allow for PAIONs partner TTY Biopharm Company Limited ("TTY") to launch remimazolam in December 2022 in this market.

Key Points: 
  • This will allow for PAIONs partner TTY Biopharm Company Limited ("TTY") to launch remimazolam in December 2022 in this market.
  • TTY Biopharm is a publicly listed pharmaceutical company with extensive expertise in the development and marketing of innovative pharmaceuticals.
  • Dr. Jim Phillips, CEO of PAION AG, commented: We are very pleased to have found in TTY Biopharm an excellent partner for the development and commercialization of our lead product in Taiwan.
  • Remimazolam, developed by PAION is an ultra-short-acting and predictable intravenous benzodiazepine sedative that has been approved and launched in many countries.

EQS-News: PAION AG enters partnership with Viatris and expands sales activities in Europe

Retrieved on: 
Sunday, November 27, 2022
Growth, Frankfurt Stock Exchange, EMA, Partnership, Physician, Patient, Angiotensin, Critical care, ISIN, Paion, Multiplicity of infection, Hypotension, Septic, Distributive shock, Medis, Security (finance), Pharmaceutical industry, Viatris, Eravacycline, Anesthesia, Remimazolam, EU

Under the terms of the collaboration agreement, on the one hand, PAION will receive a upfront payment.

Key Points: 
  • Under the terms of the collaboration agreement, on the one hand, PAION will receive a upfront payment.
  • In addition, Viatris will purchase supply of the products from PAION and also share with them the profits from product sales.
  • Commenting on the sales activities, Dr. Jim Phillips, CEO of PAION AG, said: "We are very pleased to have entered into a long-term partnership with leading global healthcare company Viatris to provide access to medicines for patients in Europe.
  • This is an important milestone for PAION to drive forward its sales activities in Europe in a targeted manner.